Literature DB >> 17885521

Contrast-enhanced cardiovascular magnetic resonance in primary and ischemic dilated cardiomyopathy.

Chiara Calore1, Luisa Cacciavillani, Giovanni Maria Boffa, Caterina Silva, Enrico Tiso, Martina Perazzolo Marra, Enrico Bacchiega, Francesco Corbetti, Sabino Iliceto.   

Abstract

OBJECTIVES: Differentiation between primary dilated cardiomyopathy and ischemic cardiomyopathy has an important clinical significance. Contrast-enhanced cardiovascular magnetic resonance can play a role in this task, identifying myocardial scarring or fibrosis as presence of delayed enhancement. The aim of the present study was to evaluate the diagnostic potential of contrast-enhanced cardiovascular magnetic resonance in differentiating dilated cardiomyopathy from ischemic cardiomyopathy.
METHODS: Contrast-enhanced cardiovascular magnetic resonance was performed in 100 patients with left ventricular dilatation and reduced systolic function: 24 had normal coronary arteries (dilated cardiomyopathy group) and 76 had significant coronary artery disease (ischemic cardiomyopathy group), with or without previous myocardial infarction.
RESULTS: In the dilated cardiomyopathy group, only seven (29%) patients showed delayed enhancement and its pattern was characterized by mid-wall, patchy or diffuse location. All patients with ischemic cardiomyopathy and prior myocardial infarction (54 subjects) showed delayed enhancement with subendocardial (n = 4) or transmural (n = 50) extension. Among the 22 patients with ischemic cardiomyopathy but without previous myocardial infarction, 13 (59%) showed either subendocardial (n = 4) or transmural (n = 9) delayed enhancement.
CONCLUSIONS: Patterns of delayed enhancement are different in dilated cardiomyopathy and ischemic cardiomyopathy, reflecting the presence of scarring or various degrees of fibrosis in left ventricular myocardium. The presence of subendocardial or transmural delayed enhancement at contrast-enhanced cardiovascular magnetic resonance allowed distinction between dilated cardiomyopathy and ischemic cardiomyopathy with high sensitivity (88%) and specificity (100%). Integration of cardiovascular magnetic resonance results with angiographic information can be useful in the identification of pathogenic mechanisms underlying left ventricular dysfunction.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17885521     DOI: 10.2459/JCM.0b013e3280101e3c

Source DB:  PubMed          Journal:  J Cardiovasc Med (Hagerstown)        ISSN: 1558-2027            Impact factor:   2.160


  11 in total

1.  Cardiac allograft vasculopathy : complications and imaging studies.

Authors:  G Di Bella; F Minutoli; S Coglitore; A Recupero; R Donato; R Caruso; P Grimaldi; S Lentini
Journal:  Herz       Date:  2011-10       Impact factor: 1.443

2.  Fragmented QRS is associated with all-cause mortality and ventricular arrhythmias in patient with idiopathic dilated cardiomyopathy.

Authors:  Jing Sha; Shu Zhang; Min Tang; Keping Chen; Xinran Zhao; Fangzheng Wang
Journal:  Ann Noninvasive Electrocardiol       Date:  2011-07       Impact factor: 1.468

3.  Relationship between fragmented QRS complexes and left ventricular systolic and diastolic functions.

Authors:  A Canga; S A Kocaman; M E Durakoğlugil; M Cetin; T Erdoğan; T Kırış; M Erden
Journal:  Herz       Date:  2013-04-17       Impact factor: 1.443

4.  The independent relationship of systemic inflammation with fragmented QRS complexes in patients with acute coronary syndromes.

Authors:  Mustafa Çetin; Sinan Altan Kocaman; Turan Erdoğan; Aytun Canga; Murtaza Emre Durakoğlugil; Ömer Şatıroğlu; Özgür Akgül; Tuncay Kırış; Yüksel Ciçek; Barış Yaylak; Sıtkı Doğan; Ismail Şahin; Mehmet Bostan
Journal:  Korean Circ J       Date:  2012-07-26       Impact factor: 3.243

5.  Short-term Prognosis of Fragmented QRS Complex in Patients with Non-ST Elevated Acute Myocardial Infarction.

Authors:  Min Li; Xiao Wang; Shu-Hua Mi; Zhe Chi; Qing Chen; Xin Zhao; Shao-Ping Nie
Journal:  Chin Med J (Engl)       Date:  2016-03-05       Impact factor: 2.628

6.  Mid wall fibrosis on CMR with late gadolinium enhancement may predict prognosis for LVAD and transplantation risk in patients with newly diagnosed dilated cardiomyopathy-preliminary observations from a high-volume transplant centre.

Authors:  Jose V Venero; Mark Doyle; Moneal Shah; Vikas K Rathi; June A Yamrozik; Ronald B Williams; Diane A Vido; Geetha Rayarao; Raymond Benza; Srinivas Murali; Jerry Glass; Peter Olson; George Sokos; Robert W W Biederman
Journal:  ESC Heart Fail       Date:  2015-07-29

7.  A model based on clinical parameters to identify myocardial late gadolinium enhancement by magnetic resonance in patients with aortic stenosis: An observational study.

Authors:  Mariya Kuk; Simon Newsome; Francisco Alpendurada; Marc Dweck; Dudley J Pennell; Vassilios S Vassiliou; Sanjay K Prasad
Journal:  JRSM Cardiovasc Dis       Date:  2020-04-27

8.  Absence and Resolution of Fragmented QRS Predict Reversible Myocardial Ischemia With Higher Probability of ST Segment Resolution in Patients With ST Segment Elevation Myocardial Infarction.

Authors:  Mustafa Cetin; Sinan Altan Kocaman; Tuncay Kiris; Turan Erdogan; Aytun Canga; Murtaza Emre Durakoglugil; Yüksel Ciçek; Sitki Dogan; Omer Satiroglu
Journal:  Korean Circ J       Date:  2012-10-31       Impact factor: 3.243

9.  Assessment of the relationship between red cell distribution width and fragmented QRS in patients with non-ST elevated acute coronary syndrome.

Authors:  Adem Bekler; Emine Gazi; Erhan Tenekecioglu; Kemal Karaagac; Burak Altun; Ahmet Temiz; Ahmet Barutçu; Tezcan Peker; Burhan Aslan; Mustafa Yılmaz
Journal:  Med Sci Monit       Date:  2014-03-13

10.  Concordant and Discordant Cardiac Magnetic Resonance Imaging Delayed Hyperenhancement Patterns in Patients with Ischemic and Non-Ischemic Cardiomyopathy.

Authors:  Eun Kyoung Kim; Sung-A Chang; Jin-Oh Choi; James Glockner; Brian Shapiro; Yeon Hyeon Choe; Nowell Fine; Shin Yi Jang; Sung-Mok Kim; Wayne Miller; Sang-Chol Lee; Jae K Oh
Journal:  Korean Circ J       Date:  2016-01-14       Impact factor: 3.243

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.